Section
This study compares outcomes after allogeneic stem cell transplantation using post-transplant cyclophosphamide in AML patients achieving first remission with one versus two induction courses, revealing similar survival but higher relapse wi
This study analyzes outcomes of azacitidine versus decitabine, with or without venetoclax, in TP53-mutant AML, revealing comparable survival outcomes and highlighting the independent prognostic impact of multi-hit TP53 status.
Circulating tumor cells (CTCs) enhance the IMS-IMWG 2025 genomic staging by identifying a disseminated high-risk phenotype in newly diagnosed multiple myeloma, improving prognostic stratification and enabling minimally invasive disease moni
This review synthesizes evidence on IL-16-driven resistance to BTK inhibitors and chemoimmunotherapy in B-cell lymphomas, highlighting the IL-16/CD9/PI3K axis as a targetable epigenetically regulated survival pathway overcoming drug resista
Arlocabtagene autoleucel (arlo-cel) is a novel GPRC5D-targeted CAR T-cell therapy showing promising efficacy and manageable safety in patients with relapsed/refractory multiple myeloma heavily pretreated with standard regimens, including pr
TP53 mutations define a high-risk AML subset with inferior survival post-allo-HCT, driven mainly by relapse. Molecular heterogeneity may guide personalized post-transplant strategies.
The presence of measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in AML significantly predicts poorer survival outcomes, highlighting its potential as a critical MRD biomarker for risk stratif
Longitudinal analysis of 371 aplastic anemia patients reveals distinct patterns of clonal hematopoiesis under immunosuppressive therapy, highlighting variable mutation dynamics, cytogenetic changes, and progression risks.
CT0590, a novel allogeneic BCMA CAR T-cell therapy armored with NKG2A to resist host NK cell attacks, demonstrates promising safety and efficacy in relapsed/refractory multiple myeloma and plasma cell leukemia, addressing key transplant rej
The phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensive
This study reveals that CSNK1A1 E98 mutations in del(5q) MDS alter kinase signaling and metabolism, creating a stress-tolerant yet inflexible hematopoietic cell state with distinct clinical features and potential therapeutic vulnerabilities
This article explores the expression and functional impact of snoRNA-derived RNAs in healthy blood formation and acute myeloid leukemia, highlighting their potential as biomarkers and therapeutic targets.
Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant gastrointestinal graft-versus-host disease (GI-GVHD). Inhibition of the retinoic acid receptor restores steroid sensitivity and improves outcomes in murin
Germline and somatic variants in DNMT3A and other CHIP genes elevate pulmonary arterial hypertension risk, including connective tissue disease-associated forms, through pro-inflammatory pathways, highlighting novel biomarkers and therapeuti
A multicenter study developed a robust exosomal microRNA-based model enabling preoperative detection of occult liver micrometastasis in pancreatic ductal adenocarcinoma, improving risk stratification and guiding treatment sequencing.
This review synthesizes evidence on testicular endocrine function in boys undergoing treatment for hematological malignancies, highlighting reversible dysfunctions, Sertoli cell maturation delay, and the need for long-term endocrine surveil
A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.
Routine DAT offers limited additional clinical value over transcutaneous bilirubin monitoring in low-risk ABO and RhD-incompatible neonates, supporting guideline shifts towards selective DAT use and emphasizing maternal antibody screening.
This article reviews the variability and comparative effectiveness of re-induction treatments in pediatric relapsed AML, highlighting the role of gemtuzumab ozogamicin and chemotherapy backbones in improving remission rates but not overall
The combination therapy of azacitidine and ruxolitinib demonstrates a 72% overall response rate in myelofibrosis patients, highlighting enhanced efficacy beyond JAK2 inhibitor monotherapy in a phase II clinical trial.
